Leap Therapeutics (NASDAQ: LPTX) is a clinical-stage biopharmaceutical company focused on acquiring and developing novel, targeted and immuno-oncology therapeutics. Their primary mission is to address significant unmet medical needs in cancer treatment. Leap's leading drug candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a key modulator in Wnt signaling pathways implicated in cancer. DKN-01 is currently being evaluated in multiple clinical trials for various cancers, particularly gastroesophageal, gynecologic, and prostate cancers, often in combination with other therapies.
The Lexington headquarters serves as the central node for Leap Therapeutics's corporate administration, research and development oversight, clinical operations management, and strategic planning.
The facility is situated in a modern life sciences campus, likely equipped with or providing access to advanced laboratory and office spaces tailored for biopharmaceutical research and development.
As a clinical-stage biotech, the work culture at Leap Therapeutics likely fosters innovation, scientific rigor, collaboration, and a strong patient-first mentality. Employees are driven by the goal of advancing treatments for difficult-to-treat cancers.
The headquarters' location in the Boston-Cambridge biotech cluster provides invaluable access to a rich ecosystem of academic research, potential industry collaborations, skilled workforce, and venture capital, all critical for growth and innovation in the biopharmaceutical sector.
Leap Therapeutics's global presence is primarily manifested through its clinical trial operations and collaborations. While its core R&D and corporate functions are centralized in the United States, the company engages with international clinical research sites, investigators, and contract research organizations (CROs) to conduct studies for its pipeline candidates like DKN-01. This global approach to clinical development allows for broader patient access and diverse data collection. They may also pursue global partnerships for drug development and commercialization.
75 Hayden Avenue, Suite C-1
Lexington
MA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Leap Therapeutics' leadership includes:
Leap Therapeutics has been backed by several prominent investors over the years, including:
In the last 12 months (from approximately mid-2023 to mid-2024), Leap Therapeutics notably strengthened its executive team with the appointment of a new Chief Financial Officer. No significant executive departures were publicly announced during this period.
Discover the tools Leap Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Leap Therapeutics appears to utilize a common corporate email format, typically combining the employee's first initial and last name.
flast@leaptx.com
Format
jonsi@leaptx.com
Example
75%
Success rate
Business Wire • May 9, 2024
Leap Therapeutics announced its financial results for the first quarter ended March 31, 2024, and provided an update on its ongoing clinical programs, particularly for DKN-01 in gastroesophageal and gynecologic cancers....more
Business Wire • April 8, 2024
Leap Therapeutics presented new clinical data on DKN-01 at the American Association for Cancer Research (AACR) Annual Meeting 2024. The data included findings from the DeFianCe study in colorectal cancer and the Part C study in gastric or gastroesophageal junction cancer....more
GlobeNewswire • August 2, 2023
Leap Therapeutics announced the appointment of Richard Termini as its new Chief Financial Officer and Treasurer, effective August 1, 2023. Mr. Termini brings over 20 years of financial leadership experience in the biopharmaceutical industry....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Leap Therapeutics, are just a search away.